person · Reporting owner

Stampacchia Otello

Disclosed activity across 12 companies

Tapewire entity: 36727
SEC CIK: 0001361712

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Gossamer Bio, Inc.GOSS · Entity 6928	10% owner · Former director.	September 16, 2019	September 18, 2019
IMMUNIC, INC.IMUX · Entity 6306	10% owner	April 12, 2019	April 22, 2019
ImageneBio, Inc.IMA · Entity 7139	Director	June 16, 2026	June 18, 2026
Kronos Bio, Inc.KRON · Entity 78257	Director	June 22, 2022	June 29, 2022
Morphic Holding, Inc.MORF · Entity 88114	Director	April 29, 2021	May 03, 2021
Nuvation Bio Inc.NUVB · Entity 4384	10% owner	February 10, 2021	February 12, 2021
Omega Alpha SPACOMEG · Entity 143846	Director · Chief Executive Officer · 10% owner	January 11, 2021	January 13, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Gossamer Bio, Inc.

Report date September 16, 2019 · Filed September 18, 2019

Jointly reported with Omega Fund V, L.P., Omega Fund V GP, L.P., Omega Fund V GP Manager, Ltd.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,737,023	Last balance in matching sequence After 2019-09-18 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2019-09-16 · Sale · Disposed 13,213 · Balance 6,806,023 F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $21.56 per share, inclusive. F4: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Effective as of September 12, 2019, Otello Stampacchia is no longer a member of the issuer's board of directors. Row 2 · 2019-09-17 · Sale · Disposed 23,400 · Balance 6,782,623 F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $22.24 per share, inclusive. F4: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Effective as of September 12, 2019, Otello Stampacchia is no longer a member of the issuer's board of directors. Row 3 · 2019-09-18 · Sale · Disposed 45,600 · Balance 6,737,023 F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $22.35 per share, inclusive. F4: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Effective as of September 12, 2019, Otello Stampacchia is no longer a member of the issuer's board of directors.

Filing footnotes · ownership attribution and instrument terms

F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $21.56 per share, inclusive.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $22.24 per share, inclusive.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $22.35 per share, inclusive.

F4: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Effective as of September 12, 2019, Otello Stampacchia is no longer a member of the issuer's board of directors.

IMMUNIC, INC.

Report date April 12, 2019 · Filed April 22, 2019

Jointly reported with Global Life Bioventure V Sarl, Omega Fund V, L.P., Omega Fund V GP, L.P., Omega Fund V GP Manager, Ltd., Lim Richard J., Nessi Claudio, Paster Anne-Mari

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,371,494	Reported balance Holding disclosure · report date 2019-04-12 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,371,494 F1: On April 12, 2019, pursuant to an Exchange Agreement, dated as of January 6, 2019, between the Issuer (then known as Vital Therapies, Inc.), Immunic AG ("Immunic"), and the shareholders of Immunic party thereto (the "Exchange Agreement"), the holders of Immunic ordinary shares exchanged all of their outstanding shares for shares of Issuer common stock, resulting in Immunic becoming a wholly-owned subsidiary of the Issuer (the "Transaction"). Immediately following the Transaction, the Issuer changed its name to "Immunic, Inc." In connection with the Transaction, the Reporting Person received shares of common stock of the Issuer. F2: The reported securities are held directly by Global Life Bioventure V S.a r.l. ("Global Life"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V, L.P. ("Omega V"), the sole owner of Global Life, Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: On April 12, 2019, pursuant to an Exchange Agreement, dated as of January 6, 2019, between the Issuer (then known as Vital Therapies, Inc.), Immunic AG ("Immunic"), and the shareholders of Immunic party thereto (the "Exchange Agreement"), the holders of Immunic ordinary shares exchanged all of their outstanding shares for shares of Issuer common stock, resulting in Immunic becoming a wholly-owned subsidiary of the Issuer (the "Transaction"). Immediately following the Transaction, the Issuer changed its name to "Immunic, Inc." In connection with the Transaction, the Reporting Person received shares of common stock of the Issuer.

F2: The reported securities are held directly by Global Life Bioventure V S.a r.l. ("Global Life"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V, L.P. ("Omega V"), the sole owner of Global Life, Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.

ImageneBio, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.45 · Expires 2036-06-16	Direct	15,600	Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 15,600 · Balance 15,600 F1: The shares vest in full upon the earlier to occur of the first anniversary of the date of grant, the date of the Issuer's next annual meeting or a change of control as defined in the Issuer's 2025 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest in full upon the earlier to occur of the first anniversary of the date of grant, the date of the Issuer's next annual meeting or a change of control as defined in the Issuer's 2025 Equity Incentive Plan.

Kronos Bio, Inc.

Report date June 22, 2022 · Filed June 29, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.53 · Expires 2032-06-21	Direct	34,000	Reported balance After 2022-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-22 · Grant · Acquired 34,000 · Balance 34,000 F1: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

Morphic Holding, Inc.

Report date April 29, 2021 · Filed May 03, 2021

Jointly reported with Omega Fund V, L.P., Omega Fund V GP, L.P., Omega Fund V GP Manager, Ltd.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,068,913	Last balance in matching sequence After 2021-04-30 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 6 source rows Row 1 · 2021-04-29 · Sale · Disposed 3,826 · Balance 2,082,245 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.75 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Row 2 · 2021-04-29 · Sale · Disposed 2,731 · Balance 2,079,514 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.02 to $54.99 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Row 3 · 2021-04-29 · Sale · Disposed 1,114 · Balance 2,078,400 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.01 to $55.69 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Row 4 · 2021-04-30 · Sale · Disposed 1,358 · Balance 2,077,042 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.60 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Row 5 · 2021-04-30 · Sale · Disposed 5,274 · Balance 2,071,768 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.61 to $55.53 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Row 6 · 2021-04-30 · Sale · Disposed 2,855 · Balance 2,068,913 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.71 to $55.82 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.75 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.02 to $54.99 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.01 to $55.69 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.60 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.61 to $55.53 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.71 to $55.82 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F8: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer.

Nuvation Bio Inc.

Report date February 10, 2021 · Filed February 12, 2021

Jointly reported with Omega Fund V, L.P., Omega Fund V GP, L.P., Omega Fund V GP Manager, Ltd., Nessi Claudio, Paster Anne-Mari, DOIG MICHELLE

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	27,712,373	Reported balance After 2021-02-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-02-10 · Conversion · Acquired 8,130,097 · Balance 27,712,373 F1: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). The transactions contemplated by the Merger Agreement are referred to herein as the "Business Combination." F2: Includes 19,582,276 shares issued in connection with the conversion of shares of Class A Common Stock in the Business Combination, as defined herein. F3: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Michelle Doig is a partner of Omega V and shares voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager, the Omega Directors and Michelle Doig disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.
Class A Common StockSEC Table I · non-derivative	Direct	28,212,373	Reported balance After 2021-02-10 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-02-10 · Grant · Acquired 500,000 · Balance 28,212,373 F4: On October 20, 2020, the Issuer entered into subscription agreements (the "Subscription Agreements") with certain investors (the "PIPE Investors") pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, as defined herein, an aggregate of $476,550,000 of the Issuer's shares of Class A Common Stock at a price of $10.00 per share, or an aggregate of 47,655,000 shares of Class A Common Stock. The Reporting Person is among the PIPE Investors. F3: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Michelle Doig is a partner of Omega V and shares voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager, the Omega Directors and Michelle Doig disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-02-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-02-10 · Conversion · Disposed 8,130,097 · Balance 0 F1: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). The transactions contemplated by the Merger Agreement are referred to herein as the "Business Combination." F5: Each share of Series A Preferred Stock stock automatically converted into Class A Common Stock on a 1-for-1 basis immediately prior to the closing of the Business Combination and has no expiration date nor conversion price.

Filing footnotes · ownership attribution and instrument terms

F1: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). The transactions contemplated by the Merger Agreement are referred to herein as the "Business Combination."

F2: Includes 19,582,276 shares issued in connection with the conversion of shares of Class A Common Stock in the Business Combination, as defined herein.

F3: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Michelle Doig is a partner of Omega V and shares voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager, the Omega Directors and Michelle Doig disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.

F4: On October 20, 2020, the Issuer entered into subscription agreements (the "Subscription Agreements") with certain investors (the "PIPE Investors") pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, as defined herein, an aggregate of $476,550,000 of the Issuer's shares of Class A Common Stock at a price of $10.00 per share, or an aggregate of 47,655,000 shares of Class A Common Stock. The Reporting Person is among the PIPE Investors.

F5: Each share of Series A Preferred Stock stock automatically converted into Class A Common Stock on a 1-for-1 basis immediately prior to the closing of the Business Combination and has no expiration date nor conversion price.

Omega Alpha SPAC

Report date January 11, 2021 · Filed January 13, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	IndirectBy Omega Alpha Management (0001831897)	501,000	Reported balance After 2021-01-11 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-01-11 · Purchase · Acquired 501,000 · Balance 501,000 F1: The reported Class A ordinary shares were purchased as Private Placement Shares by Omega Alpha Management for $10.00 per share, as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-251551). F2: These shares are held by Omega Alpha Management (the "Sponsor"). The Sponsor is governed by two managers, the reporting person to this Form 3, Otello Stampacchia, who is a director of Omega Fund VI GP Manager, Ltd. ("Omega Top GP"), which is the general partner of Omega Fund VI GP, L.P. ("Omega GP"), which is the general partner of Omega Fund VI, L.P. ("Omega VI"), the sole member of the Sponsor, and Alexandra Pearsall (together with the reporting person, the "Managers"). As such, each of Omega Top GP, Omega GP, Omega VI and the Managers has voting and investment discretion with respect to the Class B Ordinary Shares held by the Sponsor. The reporting person disclaims Section 16 beneficial ownership of the shares except to the extent, if any, of his respective pecuniary interest therein, and this report shall not be deemed an admission that any of such persons is the beneficial owner of such shares for Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The reported Class A ordinary shares were purchased as Private Placement Shares by Omega Alpha Management for $10.00 per share, as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-251551).

F2: These shares are held by Omega Alpha Management (the "Sponsor"). The Sponsor is governed by two managers, the reporting person to this Form 3, Otello Stampacchia, who is a director of Omega Fund VI GP Manager, Ltd. ("Omega Top GP"), which is the general partner of Omega Fund VI GP, L.P. ("Omega GP"), which is the general partner of Omega Fund VI, L.P. ("Omega VI"), the sole member of the Sponsor, and Alexandra Pearsall (together with the reporting person, the "Managers"). As such, each of Omega Top GP, Omega GP, Omega VI and the Managers has voting and investment discretion with respect to the Class B Ordinary Shares held by the Sponsor. The reporting person disclaims Section 16 beneficial ownership of the shares except to the extent, if any, of his respective pecuniary interest therein, and this report shall not be deemed an admission that any of such persons is the beneficial owner of such shares for Section 16 or any other purpose.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Kezar Life Sciences, Inc.

Report date June 25, 2018 · Filed June 25, 2018

Jointly reported with Omega Fund IV, L.P., Omega Fund IV GP, L.P., Omega Fund IV G.P. Manager, Ltd., Lim Richard J., Paster Anne-Mari

Section 16 reporting ended · disclosed 2018-06-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	315,489	Reported balance After 2018-06-25 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-06-25 · Conversion · Acquired 315,489 · Balance 315,489 F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.
Common StockSEC Table I · non-derivative	Direct	693,272	Reported balance After 2018-06-25 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-06-25 · Conversion · Acquired 377,783 · Balance 693,272 F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.
Common StockSEC Table I · non-derivative	IndirectBy Omega IV	693,272	Last balance in matching sequence After 2018-06-25 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2018-06-25 · Conversion · Acquired 315,489 · Balance 315,489 F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein. Row 4 · 2018-06-25 · Conversion · Acquired 377,783 · Balance 693,272 F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-06-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-06-25 · Conversion · Disposed 315,489 · Balance 0 F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy Omega IV	0	Reported balance After 2018-06-25 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-06-25 · Conversion · Disposed 315,489 · Balance 0 F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-06-25 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-06-25 · Conversion · Disposed 377,783 · Balance 0 F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy Omega IV	0	Reported balance After 2018-06-25 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-06-25 · Conversion · Disposed 377,783 · Balance 0 F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.

F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.

Lexeo Therapeutics, Inc.

Report date November 07, 2023 · Filed November 09, 2023

Jointly reported with Omega Fund VI, L.P., Omega Fund VI GP, L.P., Omega Fund VI GP Manager, Ltd., Nessi Claudio, Paster Anne-Mari

Section 16 reporting ended · disclosed 2023-11-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,415,865	Reported balance After 2023-11-07 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-11-07 · Conversion · Acquired 1,415,865 · Balance 1,415,865 F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
Common StockSEC Table I · non-derivative	Direct	1,703,078	Reported balance After 2023-11-07 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-11-07 · Conversion · Acquired 287,213 · Balance 1,703,078 F2: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
Common StockSEC Table I · non-derivative	Direct	2,157,623	Reported balance After 2023-11-07 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2023-11-07 · Purchase · Acquired 454,545 · Balance 2,157,623
Series A convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-11-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-07 · Conversion · Disposed 14,999,999 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
Series B convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-11-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-11-07 · Conversion · Disposed 2,615,533 · Balance 0 F2: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

F2: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Replimune Group, Inc.

Report date March 14, 2022 · Filed March 17, 2022

Jointly reported with Omega Fund IV, L.P., Omega Fund IV GP, L.P., Omega Fund IV G.P. Manager, Ltd.

Section 16 reporting ended · disclosed 2022-03-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Otello Stampacchia	4,763,380	Last balance in matching sequence After 2022-03-14 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2022-03-14 · Exercise / conversion · Acquired 16,500 · Balance 4,779,880 F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager. Row 2 · 2022-03-14 · Sale · Disposed 16,500 · Balance 4,763,380 F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager.
Common StockSEC Table I · non-derivative	Direct	4,673,380	Last balance in matching sequence After 2022-03-16 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 3 · 2022-03-15 · Sale · Disposed 45,000 · Balance 4,718,380 F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Row 4 · 2022-03-16 · Sale · Disposed 6,238 · Balance 4,712,142 F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Row 5 · 2022-03-16 · Sale · Disposed 38,762 · Balance 4,673,380 F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.
Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.78 · Expires 2030-04-01	IndirectBy Otello Stampacchia	16,500	Reported balance After 2022-03-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-03-14 · Exercise / conversion · Disposed 16,500 · Balance 16,500 F3: Stock options vested 100% on April 1, 2021. F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.

F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager.

F3: Stock options vested 100% on April 1, 2021.

Theseus Pharmaceuticals, Inc.

Report date October 12, 2021 · Filed October 14, 2021

Jointly reported with Omega Fund VI, L.P., Omega Fund VI GP Manager, Ltd., Nessi Claudio, Paster Anne-Mari

Section 16 reporting ended · disclosed 2021-10-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	711,479	Last balance in matching sequence After 2021-10-12 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2021-10-12 · Conversion · Acquired 523,979 · Balance 523,979 F1: Omega Fund VI, L.P. ("Omega VI") held 693,152 shares of the Issuer's Series B Preferred Stock. On October 12, 2021, the Series B Preferred Stock automatically converted into 523,979 shares of the Issuer's Common Stock on a 1-for-1.32286 reverse split basis, immediately prior to and in connection with the closing of a public offering of the Issuer's securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") and without payment of further consideration. F2: The reported securities are beneficially owned by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Each of such individuals disclaims beneficial ownership of the shares held by Omega VI. F3: As of October 12, 2021 and after giving effect to the transactions reported above, Omega VI holds less than 10% of the outstanding shares of the Issuer's Common Stock. Row 2 · 2021-10-12 · Purchase · Acquired 187,500 · Balance 711,479 F2: The reported securities are beneficially owned by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Each of such individuals disclaims beneficial ownership of the shares held by Omega VI. F3: As of October 12, 2021 and after giving effect to the transactions reported above, Omega VI holds less than 10% of the outstanding shares of the Issuer's Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-10-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-10-12 · Conversion · Disposed 693,152 · Balance 0 F1: Omega Fund VI, L.P. ("Omega VI") held 693,152 shares of the Issuer's Series B Preferred Stock. On October 12, 2021, the Series B Preferred Stock automatically converted into 523,979 shares of the Issuer's Common Stock on a 1-for-1.32286 reverse split basis, immediately prior to and in connection with the closing of a public offering of the Issuer's securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") and without payment of further consideration. F2: The reported securities are beneficially owned by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Each of such individuals disclaims beneficial ownership of the shares held by Omega VI. F3: As of October 12, 2021 and after giving effect to the transactions reported above, Omega VI holds less than 10% of the outstanding shares of the Issuer's Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: Omega Fund VI, L.P. ("Omega VI") held 693,152 shares of the Issuer's Series B Preferred Stock. On October 12, 2021, the Series B Preferred Stock automatically converted into 523,979 shares of the Issuer's Common Stock on a 1-for-1.32286 reverse split basis, immediately prior to and in connection with the closing of a public offering of the Issuer's securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") and without payment of further consideration.

F2: The reported securities are beneficially owned by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Each of such individuals disclaims beneficial ownership of the shares held by Omega VI.

F3: As of October 12, 2021 and after giving effect to the transactions reported above, Omega VI holds less than 10% of the outstanding shares of the Issuer's Common Stock.

Translate Bio, Inc.

Report date July 02, 2018 · Filed July 03, 2018

Jointly reported with Omega Fund IV, L.P., Omega Fund IV GP, L.P., Omega Fund IV G.P. Manager, Ltd., Omega Fund V, L.P., Omega Fund V GP, L.P., Omega Fund V GP Manager, Ltd., Lim Richard J., Paster Anne-Mari, Nessi Claudio

Section 16 reporting ended · disclosed 2018-07-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	979,179	Reported balance After 2018-07-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-07-02 · Conversion · Acquired 979,179 · Balance 979,179 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
Common StockSEC Table I · non-derivative	Direct	1,458,424	Reported balance After 2018-07-02 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-07-02 · Conversion · Acquired 1,458,424 · Balance 1,458,424 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
Common StockSEC Table I · non-derivative	IndirectBy Omega IV	979,179	Reported balance After 2018-07-02 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-07-02 · Conversion · Acquired 979,179 · Balance 979,179 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectBy Omega V	1,458,424	Reported balance After 2018-07-02 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2018-07-02 · Conversion · Acquired 1,458,424 · Balance 1,458,424 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-07-02 · Conversion · Disposed 2,500,000 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-02 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2018-07-02 · Conversion · Disposed 5,800,000 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Omega IV	0	Reported balance After 2018-07-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-07-02 · Conversion · Disposed 2,500,000 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-07-02 · Conversion · Disposed 1,676,348 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-02 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2018-07-02 · Conversion · Disposed 2,000,103 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Omega IV	0	Reported balance After 2018-07-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-07-02 · Conversion · Disposed 1,676,348 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-07-02 · Conversion · Disposed 1,263,484 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-07-02 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2018-07-02 · Conversion · Disposed 302,173 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy Omega IV	0	Reported balance After 2018-07-02 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-07-02 · Conversion · Disposed 1,263,484 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Omega V	0	Reported balance After 2018-07-02 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2018-07-02 · Conversion · Disposed 5,800,000 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Omega V	0	Reported balance After 2018-07-02 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2018-07-02 · Conversion · Disposed 2,000,103 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy Omega V	0	Reported balance After 2018-07-02 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2018-07-02 · Conversion · Disposed 302,173 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 07, 2021 Filed Jan 8, 2021 21:09 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	16,141	$29.98	$483,907.18	Disclosure SEC source: 0000899243-21-001159 · doc4.xml · nonDerivative · entry 3 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,876,414 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.58 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
January 06, 2021 Filed Jan 8, 2021 21:09 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	95	$31.36	$2,979.20	Disclosure SEC source: 0000899243-21-001159 · doc4.xml · nonDerivative · entry 2 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,892,555 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
January 06, 2021 Filed Jan 8, 2021 21:09 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	11,929	$30.09	$358,943.61	Disclosure SEC source: 0000899243-21-001159 · doc4.xml · nonDerivative · entry 1 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,892,650 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.85 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
January 05, 2021 Filed Jan 6, 2021 20:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	139	$32.84	$4,564.76	Disclosure SEC source: 0000899243-21-000622 · doc4.xml · nonDerivative · entry 5 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,904,579 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.66 to $32.98 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
January 05, 2021 Filed Jan 6, 2021 20:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	2,017	$32.00	$64,544.00	Disclosure SEC source: 0000899243-21-000622 · doc4.xml · nonDerivative · entry 4 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,904,718 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.62 to $32.42 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
January 05, 2021 Filed Jan 6, 2021 20:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	11,168	$30.89	$344,979.52	Disclosure SEC source: 0000899243-21-000622 · doc4.xml · nonDerivative · entry 3 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,906,735 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.56 to $31.48 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
January 04, 2021 Filed Jan 6, 2021 20:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	1,655	$33.55	$55,525.25	Disclosure SEC source: 0000899243-21-000622 · doc4.xml · nonDerivative · entry 2 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,917,903 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.11 to $34.08 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
January 04, 2021 Filed Jan 6, 2021 20:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	10,463	$32.57	$340,779.91	Disclosure SEC source: 0000899243-21-000622 · doc4.xml · nonDerivative · entry 1 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,919,558 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.07 to $33.06 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 31, 2020 Filed Jan 4, 2021 22:06 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	151	$34.55	$5,217.05	Disclosure SEC source: 0000899243-21-000122 · doc4.xml · nonDerivative · entry 5 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,930,021 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 31, 2020 Filed Jan 4, 2021 22:06 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	3,756	$33.84	$127,103.04	Disclosure SEC source: 0000899243-21-000122 · doc4.xml · nonDerivative · entry 4 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,930,172 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.43 to $34.40 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 30, 2020 Filed Jan 4, 2021 22:06 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	486	$33.75	$16,402.50	Disclosure SEC source: 0000899243-21-000122 · doc4.xml · nonDerivative · entry 3 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,933,928 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 30, 2020 Filed Jan 4, 2021 22:06 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	3,769	$33.23	$125,243.87	Disclosure SEC source: 0000899243-21-000122 · doc4.xml · nonDerivative · entry 2 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,934,414 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.72 to $33.68 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 30, 2020 Filed Jan 4, 2021 22:06 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	7,730	$32.42	$250,606.60	Disclosure SEC source: 0000899243-21-000122 · doc4.xml · nonDerivative · entry 1 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,938,183 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.71 to $32.71 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 29, 2020 Filed Dec 31, 2020 02:26 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	54	$32.87	$1,774.98	Disclosure SEC source: 0000899243-20-035543 · doc4.xml · nonDerivative · entry 4 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,945,913 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 29, 2020 Filed Dec 31, 2020 02:26 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	10,374	$31.75	$329,374.50	Disclosure SEC source: 0000899243-20-035543 · doc4.xml · nonDerivative · entry 3 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,945,967 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.43 to $32.41 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 28, 2020 Filed Dec 31, 2020 02:26 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	149	$33.25	$4,954.25	Disclosure SEC source: 0000899243-20-035543 · doc4.xml · nonDerivative · entry 2 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,956,341 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.97 to $33.25 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 28, 2020 Filed Dec 31, 2020 02:26 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	9,317	$32.34	$301,311.78	Disclosure SEC source: 0000899243-20-035543 · doc4.xml · nonDerivative · entry 1 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,956,490 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.97 to $32.81 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 24, 2020 Filed Dec 28, 2020 22:37 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	753	$33.25	$25,037.25	Disclosure SEC source: 0000899243-20-035225 · doc4.xml · nonDerivative · entry 5 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,965,807 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.17 to $33.31 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 24, 2020 Filed Dec 28, 2020 22:37 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	2,130	$32.48	$69,182.40	Disclosure SEC source: 0000899243-20-035225 · doc4.xml · nonDerivative · entry 4 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,966,560 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.10 to $33.00 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 23, 2020 Filed Dec 28, 2020 22:37 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	137	$34.95	$4,788.15	Disclosure SEC source: 0000899243-20-035225 · doc4.xml · nonDerivative · entry 3 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,968,690 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 23, 2020 Filed Dec 28, 2020 22:37 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	313	$33.81	$10,582.53	Disclosure SEC source: 0000899243-20-035225 · doc4.xml · nonDerivative · entry 2 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,968,827 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.79 to $34.22 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 23, 2020 Filed Dec 28, 2020 22:37 UTC	Morphic Holding, Inc. MORF · Entity 88114	SaleCommon Stock	8,692	$33.34	$289,791.28	Disclosure SEC source: 0000899243-20-035225 · doc4.xml · nonDerivative · entry 1 Omega Fund V, L.P. · CIK 0001641354 · Director Omega Fund V GP, L.P. · CIK 0001641355 · Director Omega Fund V GP Manager, Ltd. · CIK 0001641348 · Director Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,969,140 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.75 to $33.74 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document
December 21, 2020 Filed Apr 1, 2021 22:16 UTC	ImageneBio, Inc. IKNA · Entity 7139	GrantSeries B Preferred Stock · Derivative	12,870,933	$1.40	$17,999,999.80	Disclosure SEC source: 0000899243-21-014390 · doc4.xml · derivative · entry 3 Stampacchia Otello · CIK 0001361712 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega Fund VI, L.P. Disclosed balance after: 12,870,933 Underlying: Common Stock · 1,799,123 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · derivative.exercise_date: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Omega Fund VI, L.P. ("Omega VI"). Omega Fund VI GP, L.P. ("Omega VI GP") is the sole general partner of Omega VI. Omega Fund VI GP Manager, Ltd. ("Omega VI Manager") is the sole general partner of Omega VI GP. The Reporting Person is a director of Omega VI Manager and disclaims beneficial ownership of the shares held by Omega VI except to the extent of his pecuniary interest therein, if any. Read SEC document
October 14, 2020 Filed Oct 16, 2020 15:58 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionConvertible Promissory Note · Derivative	Not disclosed	$0.00 Strike: $16.15	$5,915,729.63	Disclosure SEC source: 0001209191-20-055046 · doc4.xml · derivative · entry 7 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 366,299 shares Expires 2022-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: Otello Stampacchia, a director of the Issuer, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interests therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 15:58 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries A Preferred Stock · Derivative	1,304,563	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055046 · doc4.xml · derivative · entry 6 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,376,313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: Otello Stampacchia, a director of the Issuer, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interests therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 15:58 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries Seed Preferred Stock · Derivative	1,522,484	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055046 · doc4.xml · derivative · entry 5 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,606,220 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: Otello Stampacchia, a director of the Issuer, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interests therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 15:58 UTC	Kronos Bio, Inc. KRON · Entity 78257	PurchaseCommon Stock	450,000	$19.00	$8,550,000.00	Disclosure SEC source: 0001209191-20-055046 · doc4.xml · nonDerivative · entry 4 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,818,283 F2 · ownership.direct: Otello Stampacchia, a director of the Issuer, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interests therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 15:58 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	366,299	$16.15	$5,915,728.85	Disclosure SEC source: 0001209191-20-055046 · doc4.xml · nonDerivative · entry 3 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,368,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.direct: Otello Stampacchia, a director of the Issuer, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interests therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 15:58 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	1,376,313	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055046 · doc4.xml · nonDerivative · entry 2 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,001,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: Otello Stampacchia, a director of the Issuer, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interests therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 15:58 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	1,606,220	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055046 · doc4.xml · nonDerivative · entry 1 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Stampacchia Otello · CIK 0001361712 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,625,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.direct: Otello Stampacchia, a director of the Issuer, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interests therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:56 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionConvertible Promissory Note · Derivative	Not disclosed	$0.00 Strike: $16.15	$5,915,729.63	Disclosure SEC source: 0001209191-20-055045 · doc4.xml · derivative · entry 7 Stampacchia Otello · CIK 0001361712 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega Fund V, LP Disclosed balance after: 0 Underlying: Common Stock · 366,299 shares Expires 2022-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reporting person, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). The reporting person may be deemed to share voting and dispositive power over the shares held by Omega L.P. The reporting person, together with Omega GP and Omega Manager, disclaims beneficial ownership of the shares held by Omega L.P. except to the extent of his pecuniary interest therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:56 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries A Preferred Stock · Derivative	1,304,563	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055045 · doc4.xml · derivative · entry 6 Stampacchia Otello · CIK 0001361712 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega Fund V, LP Disclosed balance after: 0 Underlying: Common Stock · 1,376,313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reporting person, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). The reporting person may be deemed to share voting and dispositive power over the shares held by Omega L.P. The reporting person, together with Omega GP and Omega Manager, disclaims beneficial ownership of the shares held by Omega L.P. except to the extent of his pecuniary interest therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:56 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries Seed Preferred Stock · Derivative	1,522,484	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055045 · doc4.xml · derivative · entry 5 Stampacchia Otello · CIK 0001361712 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega Fund V, LP Disclosed balance after: 0 Underlying: Common Stock · 1,606,220 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reporting person, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). The reporting person may be deemed to share voting and dispositive power over the shares held by Omega L.P. The reporting person, together with Omega GP and Omega Manager, disclaims beneficial ownership of the shares held by Omega L.P. except to the extent of his pecuniary interest therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:56 UTC	Kronos Bio, Inc. KRON · Entity 78257	PurchaseCommon Stock	450,000	$19.00	$8,550,000.00	Disclosure SEC source: 0001209191-20-055045 · doc4.xml · nonDerivative · entry 4 Stampacchia Otello · CIK 0001361712 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega Fund V, LP Disclosed balance after: 3,818,283 F2 · ownership.nature: The reporting person, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). The reporting person may be deemed to share voting and dispositive power over the shares held by Omega L.P. The reporting person, together with Omega GP and Omega Manager, disclaims beneficial ownership of the shares held by Omega L.P. except to the extent of his pecuniary interest therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:56 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	366,299	$16.15	$5,915,728.85	Disclosure SEC source: 0001209191-20-055045 · doc4.xml · nonDerivative · entry 3 Stampacchia Otello · CIK 0001361712 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega Fund V, LP Disclosed balance after: 3,368,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: The reporting person, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). The reporting person may be deemed to share voting and dispositive power over the shares held by Omega L.P. The reporting person, together with Omega GP and Omega Manager, disclaims beneficial ownership of the shares held by Omega L.P. except to the extent of his pecuniary interest therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:56 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	1,376,313	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055045 · doc4.xml · nonDerivative · entry 2 Stampacchia Otello · CIK 0001361712 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega Fund V, LP Disclosed balance after: 3,001,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reporting person, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). The reporting person may be deemed to share voting and dispositive power over the shares held by Omega L.P. The reporting person, together with Omega GP and Omega Manager, disclaims beneficial ownership of the shares held by Omega L.P. except to the extent of his pecuniary interest therein. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:56 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	1,606,220	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055045 · doc4.xml · nonDerivative · entry 1 Stampacchia Otello · CIK 0001361712 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega Fund V, LP Disclosed balance after: 1,625,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reporting person, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega V Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). The reporting person may be deemed to share voting and dispositive power over the shares held by Omega L.P. The reporting person, together with Omega GP and Omega Manager, disclaims beneficial ownership of the shares held by Omega L.P. except to the extent of his pecuniary interest therein. Read SEC document
June 18, 2020 Filed Jun 19, 2020 22:14 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $22.96	$0.00	Disclosure SEC source: 0001209191-20-038045 · doc4.xml · derivative · entry 1 Stampacchia Otello · CIK 0001361712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option will vest in full on June 18, 2021, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
April 01, 2020 Filed Apr 3, 2020 16:56 UTC	Replimune Group, Inc. REPL · Entity 4707	GrantStock Option (Right to Buy) · Derivative	16,500	$0.00 Strike: $9.78	$0.00	Disclosure SEC source: 0000899243-20-010144 · doc4.xml · derivative · entry 1 Omega Fund IV, L.P. · CIK 0001528382 · Director · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires not disclosed F1 · derivative.exercise_date: The Common Stock Options (the "Options") were granted to Otello Stampacchia in his capacity as a director of the issuer on April 1, 2020 (the "Grant Date"), with the Options vesting on the first anniversary of the Grant Date. The Options expire on the tenth anniversary of the Grant Date. The Options are held directly by Mr. Stampacchia. F1 · derivative.expiration_date: The Common Stock Options (the "Options") were granted to Otello Stampacchia in his capacity as a director of the issuer on April 1, 2020 (the "Grant Date"), with the Options vesting on the first anniversary of the Grant Date. The Options expire on the tenth anniversary of the Grant Date. The Options are held directly by Mr. Stampacchia. F1 · balance_after: The Common Stock Options (the "Options") were granted to Otello Stampacchia in his capacity as a director of the issuer on April 1, 2020 (the "Grant Date"), with the Options vesting on the first anniversary of the Grant Date. The Options expire on the tenth anniversary of the Grant Date. The Options are held directly by Mr. Stampacchia. F1 · ownership.direct: The Common Stock Options (the "Options") were granted to Otello Stampacchia in his capacity as a director of the issuer on April 1, 2020 (the "Grant Date"), with the Options vesting on the first anniversary of the Grant Date. The Options expire on the tenth anniversary of the Grant Date. The Options are held directly by Mr. Stampacchia. Read SEC document
November 18, 2019 Filed Nov 20, 2019 17:36 UTC	Replimune Group, Inc. REPL · Entity 4707	PurchaseCommon Stock	220,000	$13.61	$2,994,200.00	Disclosure SEC source: 0001179110-19-011905 · edgar.xml · nonDerivative · entry 1 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,328,939 F1 · ownership.direct: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is also a member of the issuer's board of directors. Read SEC document
September 18, 2019 Filed Sep 18, 2019 22:28 UTC	Gossamer Bio, Inc. GOSS · Entity 6928	SaleCommon Stock	45,600	$21.88	$997,636.80	Disclosure SEC source: 0000899243-19-023857 · doc4.xml · nonDerivative · entry 3 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner · Former director. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,737,023 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $22.35 per share, inclusive. F4 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Effective as of September 12, 2019, Otello Stampacchia is no longer a member of the issuer's board of directors. Read SEC document
September 17, 2019 Filed Sep 18, 2019 22:28 UTC	Gossamer Bio, Inc. GOSS · Entity 6928	SaleCommon Stock	23,400	$21.62	$505,791.00	Disclosure SEC source: 0000899243-19-023857 · doc4.xml · nonDerivative · entry 2 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner · Former director. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,782,623 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $22.24 per share, inclusive. F4 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Effective as of September 12, 2019, Otello Stampacchia is no longer a member of the issuer's board of directors. Read SEC document
September 16, 2019 Filed Sep 18, 2019 22:28 UTC	Gossamer Bio, Inc. GOSS · Entity 6928	SaleCommon Stock	13,213	$21.52	$284,330.55	Disclosure SEC source: 0000899243-19-023857 · doc4.xml · nonDerivative · entry 1 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner · Former director. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,806,023 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $21.56 per share, inclusive. F4 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Effective as of September 12, 2019, Otello Stampacchia is no longer a member of the issuer's board of directors. Read SEC document
September 11, 2019 Filed Sep 12, 2019 23:41 UTC	Gossamer Bio, Inc. GOSS · Entity 6928	SaleCommon Stock	80,403	$21.31	$1,713,629.14	Disclosure SEC source: 0000899243-19-023516 · doc4.xml · nonDerivative · entry 2 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,819,236 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.63 per share, inclusive. F3 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is also a member of the issuer's board of directors. Read SEC document
September 10, 2019 Filed Sep 12, 2019 23:41 UTC	Gossamer Bio, Inc. GOSS · Entity 6928	SaleCommon Stock	32,373	$21.00	$679,865.37	Disclosure SEC source: 0000899243-19-023516 · doc4.xml · nonDerivative · entry 1 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,899,639 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.08 per share, inclusive. F3 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is also a member of the issuer's board of directors. Read SEC document
September 06, 2019 Filed Sep 9, 2019 21:37 UTC	Gossamer Bio, Inc. GOSS · Entity 6928	SaleCommon Stock	8,700	$21.51	$187,103.07	Disclosure SEC source: 0000899243-19-023148 · doc4.xml · nonDerivative · entry 2 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,932,012 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $21.56 per share, inclusive. F3 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is also a member of the issuer's board of directors. Read SEC document
September 05, 2019 Filed Sep 9, 2019 21:37 UTC	Gossamer Bio, Inc. GOSS · Entity 6928	SaleCommon Stock	12,704	$21.60	$274,434.35	Disclosure SEC source: 0000899243-19-023148 · doc4.xml · nonDerivative · entry 1 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,940,712 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 to $21.87 per share, inclusive. F3 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is also a member of the issuer's board of directors. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:55 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries B Preferred Stock · Derivative	1,978,779	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008266 · edgar.xml · derivative · entry 5 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,978,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.By Omega Fund V, L.P., by Omega Fund GP, L.P., its general partner, by Omega Fund V GP Manager, Ltd., its general partner, /s/ Anne-Mari Paster, Director F3 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.By Omega Fund V, L.P., by Omega Fund GP, L.P., its general partner, by Omega Fund V GP Manager, Ltd., its general partner, /s/ Anne-Mari Paster, Director F3 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.By Omega Fund V, L.P., by Omega Fund GP, L.P., its general partner, by Omega Fund V GP Manager, Ltd., its general partner, /s/ Anne-Mari Paster, Director F2 · ownership.direct: Otello Stampacchia, a director of the issuer, Richard J. Lim, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interest therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:55 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries A Preferred Stock · Derivative	857,470	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008266 · edgar.xml · derivative · entry 4 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 857,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.direct: Otello Stampacchia, a director of the issuer, Richard J. Lim, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interest therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:55 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	133,333	$15.00	$1,999,995.00	Disclosure SEC source: 0001179110-19-008266 · edgar.xml · nonDerivative · entry 3 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,969,582 F2 · ownership.direct: Otello Stampacchia, a director of the issuer, Richard J. Lim, Claudio Nessi and Anne-Mari Paster are the directors of Omega Fund V GP Manager, Ltd. ("Omega Manager"), which is the sole general partner of Omega Fund GP, L.P. ("Omega GP"), which is the sole general partner of Omega Fund V, L.P. ("Omega L.P."). Such individuals may be deemed to share voting and dispositive power over the shares held by Omega L.P. Such individuals, together with Omega GP and Omega Manager, disclaim beneficial ownership of the shares held by Omega L.P. except to the extent of their respective pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.